Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Trial of Encorafenib, Cetuximab, and Nivolumab in Microsatellite Stable BRAFV600E Metastatic Colorectal Cancer (BMS-MDACC CA209-8P6/ARRAY IST-818-101X)

Next Previous
X
Search
Trial Profile

Phase I/II Trial of Encorafenib, Cetuximab, and Nivolumab in Microsatellite Stable BRAFV600E Metastatic Colorectal Cancer (BMS-MDACC CA209-8P6/ARRAY IST-818-101X)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Encorafenib (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BMS-MDACC CA209-8P6/ARRAY IST-818-101X

    • Most Recent Events

    • 18 Jul 2022 Planned primary completion date changed from 30 Jun 2024 to 30 Jun 2025.
    • 07 Jun 2022 Status changed to active, no longer recruiting , according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2022 Results (data cutoff date: 8 Feb 2022) presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top